FILING ANALYSIS · FRIDAY, NOVEMBER 6
Immunocore Holdings plc IMCR — 8-K: Results of Operations and Financial Condition
neutral
Immunocore reported Q3 net product revenue of $102.2 million, a 10% year-over-year growth, and announced the completion of target enrollment for the Phase 3 TEBE-AM trial, with topline overall survival data expected in Q2 2027. The company also has $901 million in cash, cash equivalents, and marketable securities as of September 30, 2026.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →